查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1551334

到 2030 年抗治疗性忧郁症市场预测：按治疗方式、分销管道、最终用户和地区进行的全球分析

Treatment-Resistant Depression Market Forecasts to 2030 - Global Analysis by Treatment Modality, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球抗治疗性忧郁症市场规模为 21 亿美元，预计预测期内复合年增长率为 11.8%，到 2030 年将达到 41 亿美元。

抗治疗性忧郁症(TRD) 是重度忧郁症的一种形式，对至少两种足够剂量和持续时间的抗忧郁症治疗没有充分反应。约有30%的忧郁症患者受到影响。 TRD 的特点是儘管采取了标准干预措施，但仍存在持续的忧郁症状，并且通常需要替代策略，例如药物、心理治疗、脑刺激技术和新疗法的组合。 TRD 对患者和临床医生来说是一个重大挑战，与非持久性忧郁症相比，它会导致功能障碍增加、医疗保健费用增加以及自杀行为的风险增加。

根据 2024 年 5 月发表在《美国精神病学杂誌》上的研究资料，美国接受药物治疗的重度忧郁症(MDD) 12 个月盛行率估计为 890 万人。

忧郁症盛行率增加

全球忧郁症盛行率的增加是抗治疗性忧郁症市场的主要驱动因素。根据世界卫生组织 (WHO) 统计，全球有超过 3 亿人患有忧郁症。随着忧郁症患者数量的增加，抗治疗性忧郁症患者的数量也增加。患者数量的增加为先进治疗方法创造了更大的市场，并推动了研究和开发，以找到针对这种困难疾病的更有效的治疗方法。

昂贵的治疗费用

抗治疗性忧郁症的高昂治疗费用是市场成长的主要限制因素。氯胺酮输注、经颅磁刺激和esketamine滴鼻剂等较新的治疗方法价格昂贵，而且通常不在保险范围内。例如，氯胺酮输註一个疗程可能花费数千美元。这些高昂的自付费用可能会限制许多患者获得治疗，阻碍新治疗方法的采用，并减缓市场扩张。

新疗法的研发管线

一系列针对抗治疗性忧郁症的新疗法提供了巨大的市场机会。几种有前景的化合物正处于后期临床试验中，包括裸盖菇素等致幻药物、新型麸胺酸促效剂和创新药物组合。例如，COMP360（裸盖菇素疗法）在 2 期试验中显示出正面的结果。如果这些新疗法有可能获得核准，我们可以透过扩大治疗选择、改善治疗结果和解决抗治疗性患者未满足的需求来预期市场成长。

严格的法规环境

FDA 等监管机构在核准新药，特别是具有新颖作用机制的核准时，需要大量的临床试验资料和安全性资料。这个严格的过程导致新药上市的延迟、开发成本的增加以及潜在的失败。监管障碍可能会抑制对创新治疗方法的投资，并减缓新治疗方法的推出速度。

COVID-19 的影响：

COVID-19 大流行抗治疗性忧郁症市场产生了重大影响。禁闭和社会隔离导致忧郁症和焦虑增加，病例数可能还会增加。同时，医疗保健取得和临床试验的中断正在影响治疗提供和研究进展。然而，大流行加速了远端医疗和数位心理健康解决方案的采用，为治疗提供和市场成长开闢了新途径。

零售药房业务预计将在预测期内成为最大的业务

预计零售药房领域将在预测期内主导抗治疗性忧郁症市场。零售药局为抗治疗性忧郁症患者提供便利的处方药取得途径。零售药局在配药、病患教育和药物依从性支持方面发挥重要作用。透过零售管道越来越多地获得新型抗忧郁症和辅助性治疗，促进了这一领域的成长。此外，忧郁症门诊治疗的趋势和全球零售药局连锁店的增加进一步支持了这一领域的扩张。

神经刺激治疗领域预计在预测期内复合年增长率最高

在抗治疗性忧郁症市场中，神经刺激疗法预计将具有最高的复合年增长率。这种增长是由越来越多地采用非侵入性脑刺激技术（例如经颅磁刺激（TMS）和电休克治疗（ECT））所推动的。这些方法为对传统药物治疗没有反应的患者提供了替代治疗选择。越来越多的证据支持神经刺激的有效性以及提高安全性和耐受性的技术进步正在促进这一领域的快速扩张。

占比最大的地区：

预计北美地区将在预测期内主导抗治疗性忧郁症市场。北美的优势归因于忧郁症盛行率较高、医疗基础设施完善以及较早采用新治疗方法等因素。该地区还受益于大量的研发投资、主要市场参与者的存在以及优惠的报销政策。此外，人们对心理健康的认识不断提高，对创新治疗方法的接受度也不断提高，这也有助于北美市场的领先地位。

复合年增长率最高的地区：

在预测期内，亚太地区抗治疗性忧郁症市场预计将快速成长。这一增长是由心理健康意识增强、医疗基础设施改善和医疗支出增加等因素所推动的。中国和印度等国家人口众多，忧郁症盛行率不断上升，因此存在巨大的市场机会。此外，製药公司向亚太地区的扩张以及政府不断采取的解决心理健康问题的措施也促进了亚太市场的快速成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球抗治疗性忧郁症：依治疗方式分类

  • 药物治疗
    • 选择性血清素再回收抑制剂（SSRI）
    • 正肾上腺素再回收抑制剂(SNRI)
    • 三环抗忧郁药物（TCA）
    • 单胺氧化酵素抑制剂 (MAOIs)
    • 抗精神病药
    • 情绪稳定剂
    • 氯胺酮和esketamine
    • 其他药物
  • 心理治疗
    • 认知行为治疗（CBT）
    • 人际关係治疗（IPT）
    • 心理动力疗法
    • 其他心理治疗
  • 神经刺激
    • 经颅磁刺激（TMS）
    • 深部脑部刺激（DBS）
    • 迷走神经刺激 (VNS)
    • 电痉挛治疗 (ECT)
    • 其他神经刺激疗法
  • 联合治疗

第六章 全球抗治疗性忧郁症：依通路划分

  • 医院药房
  • 零售药房
  • 网路药房
  • 远端医疗平台

第七章 全球抗治疗性忧郁症：依最终使用者分类

  • 医院
  • 专科诊所
  • 门诊
  • 研究所
  • 其他最终用户

第八章全球抗治疗性忧郁症：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、合作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第 10 章 公司概况

  • AstraZeneca
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Forest Laboratories
  • Vistagen Therapeutics, Inc.
  • Novartis
  • AbbVie Inc.
  • H. Lundbeck A/S
  • Sandoz International GmbH
  • Otsuka Pharmaceutical Co., Ltd.
  • Par Pharmaceutical
  • Mylan NV
  • Aurobindo Pharma
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC27117

According to Stratistics MRC, the Global Treatment-Resistant Depression Market is accounted for $2.1 billion in 2024 and is expected to reach $4.1 billion by 2030 growing at a CAGR of 11.8% during the forecast period. Treatment-resistant depression (TRD) is a form of major depressive disorder that does not respond adequately to at least two different antidepressant treatments of sufficient dose and duration. It affects approximately 30% of people with depression. TRD is characterized by persistent depressive symptoms despite standard interventions, often requiring alternative strategies like medication combinations, psychotherapy, brain stimulation techniques, or novel therapies. It poses significant challenges for patients and clinicians, leading to increased functional impairment, higher healthcare costs, and a greater risk of suicidal behavior compared to non-resistant depression.

According to data from a study published in the American Journal of Psychiatry in May 2024, the estimated 12-month prevalence of medication-treated major depressive disorder (MDD) in the United States was 8.9 million adults.

Market Dynamics:

Driver:

Increasing prevalence of depression

The rising prevalence of depression globally is a key driver for the treatment-resistant depression market. According to the World Health Organization, over 300 million people suffer from depression worldwide. As the number of depression cases increases, so does the subset of patients with treatment-resistant depression. This growing patient pool creates a larger market for advanced therapies and drives research and development efforts to find more effective treatments for this challenging condition.

Restraint:

High cost of treatment

The high cost of treatment for treatment-resistant depression poses a significant restraint on market growth. Novel therapies like ketamine infusions, transcranial magnetic stimulation, and esketamine nasal sprays are expensive and often not covered by insurance. For example, a course of ketamine infusions can cost thousands of dollars. These high out-of-pocket costs limit access to treatment for many patients and hinder widespread adoption of newer therapies, potentially slowing market expansion.

Opportunity:

Pipeline of novel therapies

The robust pipeline of novel therapies for treatment-resistant depression presents a significant market opportunity. Several promising compounds are in late-stage clinical trials, including psychedelics like psilocybin, new glutamatergic agents, and innovative drug combinations. For instance, COMP360 (psilocybin therapy) has shown positive results in phase 2 trials. The potential approval of these novel treatments could expand treatment options, improve outcomes, and drive market growth by addressing the unmet needs of treatment-resistant patients.

Threat:

Stringent regulatory environment

Regulatory agencies like the FDA require extensive clinical trial data and safety profiles for new drug approvals, especially for novel mechanisms of action. This rigorous process can lead to delays, increased development costs, and potential failures in bringing new treatments to market. The regulatory hurdles may discourage investment in innovative therapies and slow the pace of new treatment options becoming available.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the treatment-resistant depression market. Lockdowns and social isolation have led to increased rates of depression and anxiety, potentially expanding the patient pool. Simultaneously, disruptions in healthcare access and clinical trials have affected treatment delivery and research progress. However, the pandemic has also accelerated the adoption of telemedicine and digital mental health solutions, opening new avenues for treatment delivery and market growth.

The retail pharmacies segment is expected to be the largest during the forecast period

The retail pharmacies segment is projected to dominate the treatment-resistant depression market during the forecast period. Retail pharmacies offer convenient access to prescription medications for patients with treatment-resistant depression. They play a crucial role in medication dispensing, patient education, and adherence support. The increasing availability of novel antidepressants and adjunctive therapies through retail channels contributes to this segment's growth. Additionally, the trend towards outpatient management of depression and the rising number of retail pharmacy chains globally further drive the expansion of this segment.

The neurostimulation segment is expected to have the highest CAGR during the forecast period

The neurostimulation segment is anticipated to experience the highest CAGR in the treatment-resistant depression market. This growth is driven by the increasing adoption of non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). These methods offer alternative treatment options for patients who have not responded to traditional pharmacotherapy. The growing body of evidence supporting the efficacy of neurostimulation techniques, coupled with technological advancements improving their safety and tolerability, contributes to the rapid expansion of this segment.

Region with largest share:

During the forecast period, the North American region is expected to dominate the treatment-resistant depression market. North America's dominance can be attributed to factors such as the high prevalence of depression, well-established healthcare infrastructure, and early adoption of novel therapies. The region also benefits from significant research and development investments, the presence of key market players, and favorable reimbursement policies. Additionally, increased awareness about mental health and growing acceptance of innovative treatments contribute to North America's leading position in the market.

Region with highest CAGR:

During the forecast period, the Asia Pacific region is expected to witness rapid growth in the treatment-resistant depression market. This growth is driven by factors such as increasing awareness about mental health, improving healthcare infrastructure, and rising healthcare expenditure. The large population base and growing prevalence of depression in countries like China and India present significant market opportunities. Additionally, the expansion of pharmaceutical companies into the region and increasing government initiatives to address mental health issues contribute to the rapid market growth in Asia Pacific.

Key players in the market

Some of the key players in Treatment-Resistant Depression market include AstraZeneca, Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb Company, Forest Laboratories, Vistagen Therapeutics, Inc., Novartis, AbbVie Inc., H. Lundbeck A/S, Sandoz International GmbH, Otsuka Pharmaceutical Co., Ltd., Par Pharmaceutical, Mylan N.V., Aurobindo Pharma, and Teva Pharmaceutical Industries Ltd.

Key Developments:

In August 2024, AbbVie announced that it has completed its acquisition of Cerevel Therapeutics. With the completion of the acquisition, Cerevel is now part of AbbVie. "AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond," said Robert A. Michael, chief executive officer, AbbVie.

In July 2024, Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO(R) (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD). Nearly 30 percent of the estimated 280 million people worldwide living with major depressive disorder (MDD) have TRD,1 which occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.

In December 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR(R) (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant.

Treatment Modalities Covered:

  • Pharmacotherapy
  • Psychotherapy
  • Neurostimulation
  • Combination Therapies

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Telemedicine Platforms

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Outpatient Clinics
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Treatment-Resistant Depression Market, By Treatment Modality

  • 5.1 Introduction
  • 5.2 Pharmacotherapy
    • 5.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 5.2.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 5.2.3 Tricyclic Antidepressants (TCAs)
    • 5.2.4 Monoamine Oxidase Inhibitors (MAOIs)
    • 5.2.5 Antipsychotics
    • 5.2.6 Mood Stabilizers
    • 5.2.7 Ketamine and Esketamine
    • 5.2.8 Other Pharmacotherapies
  • 5.3 Psychotherapy
    • 5.3.1 Cognitive Behavioral Therapy (CBT)
    • 5.3.2 Interpersonal Therapy (IPT)
    • 5.3.3 Psychodynamic Therapy
    • 5.3.4 Other Psychotherapies
  • 5.4 Neurostimulation
    • 5.4.1 Transcranial Magnetic Stimulation (TMS)
    • 5.4.2 Deep Brain Stimulation (DBS)
    • 5.4.3 Vagus Nerve Stimulation (VNS)
    • 5.4.4 Electroconvulsive Therapy (ECT)
    • 5.4.5 Other Neurostimulation Therapies
  • 5.5 Combination Therapies

6 Global Treatment-Resistant Depression Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Hospital Pharmacies
  • 6.3 Retail Pharmacies
  • 6.4 Online Pharmacies
  • 6.5 Telemedicine Platforms

7 Global Treatment-Resistant Depression Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Specialty Clinics
  • 7.4 Outpatient Clinics
  • 7.5 Research Institutes
  • 7.6 Other End Users

8 Global Treatment-Resistant Depression Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AstraZeneca
  • 10.2 Pfizer Inc.
  • 10.3 GlaxoSmithKline plc
  • 10.4 Eli Lilly and Company
  • 10.5 Johnson & Johnson
  • 10.6 Bristol-Myers Squibb Company
  • 10.7 Forest Laboratories
  • 10.8 Vistagen Therapeutics, Inc.
  • 10.9 Novartis
  • 10.10 AbbVie Inc.
  • 10.11 H. Lundbeck A/S
  • 10.12 Sandoz International GmbH
  • 10.13 Otsuka Pharmaceutical Co., Ltd.
  • 10.14 Par Pharmaceutical
  • 10.15 Mylan N.V.
  • 10.16 Aurobindo Pharma
  • 10.17 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Treatment-Resistant Depression Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Treatment-Resistant Depression Market Outlook, By Treatment Modality (2022-2030) ($MN)
  • Table 3 Global Treatment-Resistant Depression Market Outlook, By Pharmacotherapy (2022-2030) ($MN)
  • Table 4 Global Treatment-Resistant Depression Market Outlook, By Selective Serotonin Reuptake Inhibitors (SSRIs) (2022-2030) ($MN)
  • Table 5 Global Treatment-Resistant Depression Market Outlook, By Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (2022-2030) ($MN)
  • Table 6 Global Treatment-Resistant Depression Market Outlook, By Tricyclic Antidepressants (TCAs) (2022-2030) ($MN)
  • Table 7 Global Treatment-Resistant Depression Market Outlook, By Monoamine Oxidase Inhibitors (MAOIs) (2022-2030) ($MN)
  • Table 8 Global Treatment-Resistant Depression Market Outlook, By Antipsychotics (2022-2030) ($MN)
  • Table 9 Global Treatment-Resistant Depression Market Outlook, By Mood Stabilizers (2022-2030) ($MN)
  • Table 10 Global Treatment-Resistant Depression Market Outlook, By Ketamine and Esketamine (2022-2030) ($MN)
  • Table 11 Global Treatment-Resistant Depression Market Outlook, By Other Pharmacotherapies (2022-2030) ($MN)
  • Table 12 Global Treatment-Resistant Depression Market Outlook, By Psychotherapy (2022-2030) ($MN)
  • Table 13 Global Treatment-Resistant Depression Market Outlook, By Cognitive Behavioral Therapy (CBT) (2022-2030) ($MN)
  • Table 14 Global Treatment-Resistant Depression Market Outlook, By Interpersonal Therapy (IPT) (2022-2030) ($MN)
  • Table 15 Global Treatment-Resistant Depression Market Outlook, By Psychodynamic Therapy (2022-2030) ($MN)
  • Table 16 Global Treatment-Resistant Depression Market Outlook, By Other Psychotherapies (2022-2030) ($MN)
  • Table 17 Global Treatment-Resistant Depression Market Outlook, By Neurostimulation (2022-2030) ($MN)
  • Table 18 Global Treatment-Resistant Depression Market Outlook, By Transcranial Magnetic Stimulation (TMS) (2022-2030) ($MN)
  • Table 19 Global Treatment-Resistant Depression Market Outlook, By Deep Brain Stimulation (DBS) (2022-2030) ($MN)
  • Table 20 Global Treatment-Resistant Depression Market Outlook, By Vagus Nerve Stimulation (VNS) (2022-2030) ($MN)
  • Table 21 Global Treatment-Resistant Depression Market Outlook, By Electroconvulsive Therapy (ECT) (2022-2030) ($MN)
  • Table 22 Global Treatment-Resistant Depression Market Outlook, By Other Neurostimulation Therapies (2022-2030) ($MN)
  • Table 23 Global Treatment-Resistant Depression Market Outlook, By Combination Therapies (2022-2030) ($MN)
  • Table 24 Global Treatment-Resistant Depression Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 25 Global Treatment-Resistant Depression Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 26 Global Treatment-Resistant Depression Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 27 Global Treatment-Resistant Depression Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 28 Global Treatment-Resistant Depression Market Outlook, By Telemedicine Platforms (2022-2030) ($MN)
  • Table 29 Global Treatment-Resistant Depression Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 Global Treatment-Resistant Depression Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 31 Global Treatment-Resistant Depression Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 32 Global Treatment-Resistant Depression Market Outlook, By Outpatient Clinics (2022-2030) ($MN)
  • Table 33 Global Treatment-Resistant Depression Market Outlook, By Research Institutes (2022-2030) ($MN)
  • Table 34 Global Treatment-Resistant Depression Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.